Hypofractionated radiotherapy for non-metastatic bone and soft tissue sarcomas

Area of Science:

• Oncology
• Radiation Oncology
• Skeletal System Neoplasms

Background:

• Soft tissue and bone sarcomas are rare malignancies requiring effective treatment strategies.
• Hypofractionated radiotherapy offers a potentially advantageous dose fractionation schedule.

Purpose of the Study:

• To assess the efficacy and toxicity of hypofractionated radiotherapy for non-metastatic soft tissue and bone sarcomas.
• To identify prognostic factors for local recurrence-free survival.

Main Methods:

• Retrospective analysis of 30 patients treated with hypofractionated radiotherapy between 2007 and 2015.
• Treatment included primary, reirradiation, or boost doses for sarcomas, predominantly in head and neck and retroperitoneal sites.
• Median dose was 35Gy in 3-5 fractions, with a median follow-up of 21 months.

Main Results:

• One- and 2-year overall survival rates were 75% and 52%, respectively.
• One- and 2-year local recurrence-free survival rates were 59% and 48%.
• Tumor size, treatment intent, and reirradiation status were significant prognostic factors for local recurrence-free survival; severe toxicity (Grade 3 trismus) was rare.

Conclusions:

• Hypofractionated radiotherapy is a safe and feasible treatment option for bone and soft tissue sarcomas.
• The modality demonstrates potential for achieving favorable local control and survival outcomes.
• It is a viable strategy for both primary treatment and reirradiation scenarios.